But, some therapies express some more serious AEs, studies have shown that major severe AEs of T-DM1 + pertuzumab ± taxane included thrombocytopenia, neutropenia, fatigue, increased ALT, anemia and peripheral neuropathy [57]. This evidence concerns the gene GPT and neutropenia.